Introduction: Aixingde Biotechnology (Beijing) Co., Ltd. was established on 20 14, and its headquarters is located in Silicon Valley Center, California, USA. As a new leader in molecular pathological diagnosis, RNAscope has been developed. Patent technology. This is one of the major advances in the field of in-situ hybridization, which can be applied to the field of precision medicine. RNAscope？ In-situ hybridization quantification of RNA at single-cell and single-molecule level is realized, with high sensitivity, high specificity, single-cell multiplex quantification and automatic Qualcomm quantification. It is an ideal platform for downstream transformation research such as NGS and chips. Use RNAscope? The study of RNA biomarkers can be applied to basic medical fields such as tumor, infection and immunity, nerve, stem cells and development, non-coding RNA, epigenetics and so on. More than 780 high-level documents have been published in internationally renowned journals such as Nature and Science.
Legal Representative: Brenda ·flo.
Established: 2014-11-06.
Registered capital: 700,000 USD.
Industrial and commercial registration number:11000450271446.
Type of enterprise: limited liability company (wholly owned by foreign legal person)
Company address: Floor 2, Building No.26, Xihuan South Road, Beijing Economic and Technological Development Zone 15.